Current Status of Islet Transplantation

Paolo Cravedi, Piero Ruggenenti, Andrea Remuzzi, Giuseppe Remuzzi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Islet transplantation has been proposed as a therapeutic option for patients with type 1 diabetes mellitus who have poor glycemic control with insulin therapy. The procedure is generally effective in reducing the frequency and severity of hypoglycemic episodes, but has a disappointingly low success rate in providing persistent insulin independence. Other issues that should be taken into account when considering islet transplantation include the side effects of the immunosuppressive therapy, alloimmunization, and the high costs. Even more importantly, whether islet transplantation prevents the progression of diabetic micro- and macrovascular complications more effectively than strict glycemic control with insulin is largely unknown yet. Until this evidence is provided, pancreatic islet transplantation should be considered as an experimental procedure, whose indications are limited to a highly selected group of type 1 diabetic patients with life-threatening hypoglycemic episodes.

Original languageEnglish
Title of host publicationRegenerative Medicine Applications in Organ Transplantation
PublisherElsevier Inc.
Pages583-598
Number of pages16
ISBN (Print)9780123985231
DOIs
Publication statusPublished - 2014

Fingerprint

Islets of Langerhans Transplantation
Insulin
Hypoglycemic Agents
Immunosuppressive Agents
Medical problems
Type 1 Diabetes Mellitus
Therapeutics
Costs and Cost Analysis
Costs

Keywords

  • Diabetic complications
  • Immunosuppression
  • Pancreas
  • Pancreatic islet transplantation
  • Type 1 diabetes mellitus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cravedi, P., Ruggenenti, P., Remuzzi, A., & Remuzzi, G. (2014). Current Status of Islet Transplantation. In Regenerative Medicine Applications in Organ Transplantation (pp. 583-598). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-398523-1.00040-9

Current Status of Islet Transplantation. / Cravedi, Paolo; Ruggenenti, Piero; Remuzzi, Andrea; Remuzzi, Giuseppe.

Regenerative Medicine Applications in Organ Transplantation. Elsevier Inc., 2014. p. 583-598.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cravedi, P, Ruggenenti, P, Remuzzi, A & Remuzzi, G 2014, Current Status of Islet Transplantation. in Regenerative Medicine Applications in Organ Transplantation. Elsevier Inc., pp. 583-598. https://doi.org/10.1016/B978-0-12-398523-1.00040-9
Cravedi P, Ruggenenti P, Remuzzi A, Remuzzi G. Current Status of Islet Transplantation. In Regenerative Medicine Applications in Organ Transplantation. Elsevier Inc. 2014. p. 583-598 https://doi.org/10.1016/B978-0-12-398523-1.00040-9
Cravedi, Paolo ; Ruggenenti, Piero ; Remuzzi, Andrea ; Remuzzi, Giuseppe. / Current Status of Islet Transplantation. Regenerative Medicine Applications in Organ Transplantation. Elsevier Inc., 2014. pp. 583-598
@inbook{85265877348f44e288ba3ec3d6dffa05,
title = "Current Status of Islet Transplantation",
abstract = "Islet transplantation has been proposed as a therapeutic option for patients with type 1 diabetes mellitus who have poor glycemic control with insulin therapy. The procedure is generally effective in reducing the frequency and severity of hypoglycemic episodes, but has a disappointingly low success rate in providing persistent insulin independence. Other issues that should be taken into account when considering islet transplantation include the side effects of the immunosuppressive therapy, alloimmunization, and the high costs. Even more importantly, whether islet transplantation prevents the progression of diabetic micro- and macrovascular complications more effectively than strict glycemic control with insulin is largely unknown yet. Until this evidence is provided, pancreatic islet transplantation should be considered as an experimental procedure, whose indications are limited to a highly selected group of type 1 diabetic patients with life-threatening hypoglycemic episodes.",
keywords = "Diabetic complications, Immunosuppression, Pancreas, Pancreatic islet transplantation, Type 1 diabetes mellitus",
author = "Paolo Cravedi and Piero Ruggenenti and Andrea Remuzzi and Giuseppe Remuzzi",
year = "2014",
doi = "10.1016/B978-0-12-398523-1.00040-9",
language = "English",
isbn = "9780123985231",
pages = "583--598",
booktitle = "Regenerative Medicine Applications in Organ Transplantation",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Current Status of Islet Transplantation

AU - Cravedi, Paolo

AU - Ruggenenti, Piero

AU - Remuzzi, Andrea

AU - Remuzzi, Giuseppe

PY - 2014

Y1 - 2014

N2 - Islet transplantation has been proposed as a therapeutic option for patients with type 1 diabetes mellitus who have poor glycemic control with insulin therapy. The procedure is generally effective in reducing the frequency and severity of hypoglycemic episodes, but has a disappointingly low success rate in providing persistent insulin independence. Other issues that should be taken into account when considering islet transplantation include the side effects of the immunosuppressive therapy, alloimmunization, and the high costs. Even more importantly, whether islet transplantation prevents the progression of diabetic micro- and macrovascular complications more effectively than strict glycemic control with insulin is largely unknown yet. Until this evidence is provided, pancreatic islet transplantation should be considered as an experimental procedure, whose indications are limited to a highly selected group of type 1 diabetic patients with life-threatening hypoglycemic episodes.

AB - Islet transplantation has been proposed as a therapeutic option for patients with type 1 diabetes mellitus who have poor glycemic control with insulin therapy. The procedure is generally effective in reducing the frequency and severity of hypoglycemic episodes, but has a disappointingly low success rate in providing persistent insulin independence. Other issues that should be taken into account when considering islet transplantation include the side effects of the immunosuppressive therapy, alloimmunization, and the high costs. Even more importantly, whether islet transplantation prevents the progression of diabetic micro- and macrovascular complications more effectively than strict glycemic control with insulin is largely unknown yet. Until this evidence is provided, pancreatic islet transplantation should be considered as an experimental procedure, whose indications are limited to a highly selected group of type 1 diabetic patients with life-threatening hypoglycemic episodes.

KW - Diabetic complications

KW - Immunosuppression

KW - Pancreas

KW - Pancreatic islet transplantation

KW - Type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84902906048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902906048&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-398523-1.00040-9

DO - 10.1016/B978-0-12-398523-1.00040-9

M3 - Chapter

AN - SCOPUS:84902906048

SN - 9780123985231

SP - 583

EP - 598

BT - Regenerative Medicine Applications in Organ Transplantation

PB - Elsevier Inc.

ER -